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CORRESPONDENCE
Re: Dacron or ePTFE for Femoro-popliteal Above-Knee
Bypass Grafting: Short- and Long-term Results of
a Multicentre Randomised Trial, van Det et al. in Eur J
Vasc Endovasc Surg (2009) 37, 457e463
Dear Sir,
I read with interest the paper by the above authors that
challenges the more conventional use of ePTFE for pros-
thetic above-knee femoropopliteal bypasses. A few issues
arise: firstly, the use of grafts of 6 mm diameter when an
8 mm graft is an option, which is not an unconventional one.
The authors have also ignored the issue of heparin-bonded
ePTFE grafts such as the Gore Propaten vascular graft in
the discussion, which has demonstrated 84% and 91% 1-year
primary patency rates,1,2 which is also supported on a
haematological basis.3 This is particularly interesting given
the study was also funded by Gore. Again, this issue was not
looked at in reference 13 of their paper, which was powered
for non-inferiority of Dacron as compared to ePTFE.
It is quite possible that once 8 mm grafts are used, the
increase in flow rates, which would be about 1.8-fold based
on the steady flow equation (notwithstanding the non-
Newtonian flow characteristics) would influence patency
rates, as would heparin- binding onto the ePTFE graft.
Given the time of the study (1992e96) and the changes in
the heparin-bonding technology it may be that the results
of this no doubt detailed study are already redundant. It
would be interesting to see what more contemporary
studies in a similar format would show when using the Gore
Propaten graft.
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Response to Letter to Editor
Dear Sir,
We would like to thank Dr Chaudhuri for his in-depth
response on our recent publication ‘‘Dacron or ePTFE for
femoro-popliteal above-knee bypass grafting: short and
long-term results of a multicentre randomised trial.’’ Eur J
Vasc Endovasc Surg 2009; 37: 457e463.
Indeed it was mentioned that the patency rates with
large-caliber prosthetic grafts in the fem-distal position
(8 mm instead of 6 mm) were maybe better.1,2 Unfortu-
nately all these studies were flawed by nonrandomised
design and potential selection bias. There is no level 1
evidence which clearly showed the better results of 8 mm
prostheses in the femoro-distal position.
We agree that new graft technologies might give better
results compared to both, the standard Dacron and ePTFE,
we used in our study. The older vascular surgeons remem-
bered the ‘‘strong expert opinion’’ that patency rates with
PTFE femoro-popliteal bypass above and below the knee
were equal to or better than those with the same operation
performed with saphenous vein.3 This ‘‘evidence’’ was the
background of our prospective RCT which clearly showed
the opposite of the opinion of the experts in the 80th. Our
group was also involved in the prospective non-consecutive
cohort study of the GoreeTex Propaten Vascular Graft in
the femoro-distal position. The design of this study lodged
all the potential risks of bias.4
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